Ready, set, grow: These are the biotech plants you can buy now

This spring I am looking forward to growing some biotech in my backyard for the first time. It’s possible because of startups that have started selling genetically engineered plants directly to consumers, including a bright-purple tomato and a petunia that glows in the dark.

This week, for $73, I ordered both by pressing a few buttons online.

Biotech seeds have been a huge business for a while. In fact, by sheer mass, GMOs are probably the single most significant product of genetic engineering ever. Except most of us aren’t planting rows of cotton or corn that can resist worms or survive a spritz of RoundUp, the big gene-splicing innovations that companies like Monsanto and Pioneer Hi-Bred first introduced in the 1990s.

What makes these new plants different is that you can buy them directly from their creators and then plant them in the yard, on a balcony, or just in a pot. 

caprese salad in a bowl made with halved yellow, red and purple-fleshed cherry tomatoes
Purple tomatoes developed by Norfolk Health Produce.
NORFOLK HEALTHY PRODUCE

Purple tomato

Starting off my biotech shopping spree, I first spent $20 to order 10 tomato seeds from Norfolk Health Produce, a small company in Davis, California, that created what it calls the Purple Tomato. The seeds have a gene introduced from a snapdragon flower, which adds a nutrient, anthocyanin, that also gives the fruits their striking color.

According to Channa S. Prakash, a geneticist and dean at Tuskegee University, the tomato is the “the first-of-its kind GMO food crop marketed directly to home gardeners.”   

The CEO of the company, Nathan Pumplin, was packing seeds when I reached him by phone. He claimed that anthocyanin has health benefits—it’s an antioxidant—but he agreed that the color is a useful sales pitch.

“I don’t need to make a label that says this red tomato is better for you than the other red tomato,” says Pumplin. “We can simply put out the purple tomato, and people say, ‘Oh my gosh, this tomato is purple.’ Its beauty is a distinguishing characteristic that people can just immediately see and understand.”

There is a plan to mass-produce the purple tomatoes for sale in supermarkets. But Pumplin says the company couldn’t ignore thousands of requests from regular gardeners. “It’s not the main focus of our business, but we are very interested in having people grow these at home,” he says. And “if home gardeners want to save the seed and replant it in their gardens for their own use, that is okay.”

couple in their glowing garden of gmo petunias
A promotional video for Light Bio’s firefly petunia.
LIGHT BIO

Glowing flower

I next decided to shell out for the “firefly petunia,” so called because the plant is supposed to glow in the dark. It’s sold by Light Bio, a startup backed by the venture capital firm NFX .

The plant is such a novelty that it’s being sold in a preorder, with promises they will arrive by May. One petunia plant costs $29 plus $24 for shipping. The company’s marketing promises that your plant will unveil “mesmerizing luminescence after dusk” and that “its soothing light is produced from living energy, cultivating a deeper connection with the inner life of the plant.” 

Finally, “Your nurturing care will be rewarded with even greater brilliance.”

It joins a short list of ornamental plants with gene modifications. Another is an orange petunia, approved in the US in 2021, that got its unusual color from a corn gene. (When some copies got loose prior to approval, officials in the US and Europe demanded its eradication in what became known as “the petunia carnage.”) 

Karen Sarkisyan, a synthetic biologist at the MRC Laboratory of Medical Sciences in the UK, is one of the petunia’s creators, and also the chief scientist of Light Bio. His lab is interested in using bioluminescence as a reporter system—a plant could reveal, for instance, how it responds to a toxin or viral infection in lab experiments. 

“In general, we’re trying to make useful things, so this is more of an exception,” he says of the firefly petunia. “The motivation was more about merging biology and art, rather than utility.”

Like a lot of things in biotech, making a glowing petunia was not easy to do—it’s the seemingly sudden result of decades of research into the chemistry that permits certain plants and animals to glow faintly.

Imposing those genetic circuits on plants did not work too well at first. Several years ago, for instance, a Kickstarter project that raised nearly $500,000 to make glowing roses failed to deliver on its promises after the project proved too difficult.

 “It was fairly obvious … that there was no good technology at that time,” says Sarkisyan, who later played a role in discovering genes from a glowing fungus which, after being added to a petunia, made it shine brightly enough to work as a novelty item.

That work continues. Sarkisyan says the company is working on “increasing the brightness and making more colors.” It’s also working on making other types of plants glow, although which ones remain a secret. “I cannot really comment on specific species we’re working on,” he says, although he did show me a photo of a spectacular glowing chrysanthemum.

side view of a genetically modified glowing plant at night
Plants made by Light Bio.
LIGHT BIO

Sarkisyan told me he sometimes likes to relax among the glowing plants and have a meditative experience. Ironically, he can only do that in the lab and not at home, since he lives in the UK. The country, which takes a stricter view on GMOs, has not approved the plants for sale (neither has Europe).

But he thinks the petunia could win over critics. “Especially with all the talk and concerns about the GM stuff, this is the first time there can be a safe, friendly, pleasant GM house plant in every home,” he says. “We think it’s a very interesting project because it is one of the first in consumer biotech. I do think we will see more and more in the future.”

My tomato seeds and glowing petunia haven’t arrived in the mail yet, and there’s still snow where I am. But come spring, I hope to be putting my first biotech crop in the ground. 

Uruguay wants to use gene drives to eradicate devastating screwworms

On a warm, sunny day in Montevideo, Uruguay, the air is smogless and crisp. Inside a highly secured facility at the National Institute of Agricultural Research (INIA) are a sophisticated gene gun, giant microscopes, and tens of thousands of gene-edited flies, their bright blue wings fluttering against the walls of their small, white, netted cages.

These flies—shown to me on video by an INIA veterinarian, Alejo Menchaca—are a new weapon that may soon be unleashed against an enemy that kills cattle and costs the livestock industry millions of dollars every year: the New World screwworm, a parasite common in parts of South America and the Caribbean. 

When a female screwworm fly attacks cattle, it lays eggs, which hatch and turn into worm-like larvae that screw down into the host animal, feeding on flesh along their way and damaging the animal’s skin. Left untreated, the animals eventually die in excruciating agony. 

But Menchaca and colleagues have a plan. Using the genome-editing system CRISPR, they’ve developed what’s known as a gene drive, a type of genetic element that manipulates the reproductive process to spread farther and faster than an ordinary gene. They are about to move into the next stage of caged trials in the lab, with a view to eventually using the genetic tool to decimate the screwworm fly population. They have received a $450,000 grant from the Inter-American Development Bank (IDB) for the research.

“With gene drives, we can control these pests in precise and effective ways,” says Menchaca.

The scientific team in Uruguay poses in a lab.

COURTESY OF ALEJO MENCHACA

Gene drives occur naturally in the wild, but the technology for making them deliberately is new and still pretty controversial. CRISPR allows scientists to cut specific genes in any organism’s DNA and replace them with new sequences. It can be used to tweak an animal’s DNA in a way that affects the species’ survival, often by making the females sterile, when it spreads in the population through breeding. 

Some organizations have been trying to develop gene drives to eradicate mosquitoes. Target Malaria, supported by the Seattle-based Bill & Melinda Gates Foundation (BMGF), is currently the most advanced gene-drive project in the world. But even then, they have never gone beyond caged trials. The process of getting permission for field release efforts has crawled.    

In 2020, the INIA researchers received permission from the Uruguayan government to test their techniques through the country’s existing National Program for Control of Screwworms. Right now, they’re experimenting with different components of the gene drive in gene-edited screwworm flies in the lab. The plan is to create a population of male screwworms with edited versions of genes that are essential for fertility in the female screwworms. When the engineered males are released into the wild, they should mate with females and pass on that gene.

Over successive generations, more and more female screwworms will inherit copies of the gene drive and become sterile, causing a population crash. 

“The thing that’s attractive is if you knock a gene drive into the female, you could disrupt female development,” says Maxwell Scott, an entomologist at North Carolina State University who is working with the Uruguayan team. “It’s potentially a very efficient system.”

The situation is urgent. In July of last year, Panama declared a state of animal health emergency amid outbreaks of cattle screwworm throughout the country. And this February, more than 200 cases of screwworm attacks on animals were reported in Costa Rica, prompting the government to declare an emergency as well. In Uruguay, screwworm flies cost the livestock industry $40 million to $154 million a year. Agricultural export is the linchpin of Uruguay’s economy—over 80% of the goods the nation exports are agricultural products. Beef, which accounts for 20% of that, is worth $2.5 billion a year. 

That makes the country’s search for new tools to combat the pests even more critical, says Carmine Paolo De Salvo, a rural development expert at the IDB. “The [Uruguayan] government is under constant pressure to do something about it,” he says.

Scientists have been trying to tackle screwworms for decades. One method, known as the sterile insect technique (SIT), was developed by researchers at the US Department of Agriculture in the 1950s. SIT involves sterilizing male screwworm flies with radiation. Then, using airplanes, the DNA-damaged males are dropped on the area of infestation. When they mate with wild female flies, the eggs that are produced do not hatch, slowing population growth and preventing the spread of the parasite.

That approach has worked in many countries, including parts of Central America, freeing livestock and wildlife by the millions from the painful grip of the pests. In the US, an area-wide eradication program using SIT worked so well that in 1966, the USDA declared screwworm eradicated within the nation’s borders. The benefits to the livestock industry were immense: producers saved up to $900 million, and the health of both wild and farm animals improved. 

Even with sterile males, eradicating screwworms remains a stubborn challenge, however. To prevent the screwworms from returning, the US—along with Central and South American countries—still runs a permanent barrier zone of sterile flies on the Panama-Colombia border, requiring a continuous supply of billions of flies every year. This effort is too expensive, and it’s simply not powerful enough to eradicate screwworm in South America, where the pests are firmly established and difficult to surveil, researchers say. So the search has been on for alternative tools.

Screwworm flies are seen in a laboratory.

COURTESY OF ALEJO MENCHACA

It was Kevin Esvelt, a pioneering leader in CRISPR gene-drive systems, who first turned the team on to the idea of using one. Esvelt had been experimenting with engineering localized versions of gene drives to target Lyme disease in the US when he met the team of Uruguayan researchers on a tour of the MIT Media Lab. Shortly after that meeting, Esvelt was on a plane to Uruguay, where he met Menchaca and convinced Uruguayan officials to initiate a gene drive project to eradicate screwworms. This would have the advantage over SIT because while SIT reduces the number of successful births, the infertility conferred by the gene drive passes through multiple generations.

The team is looking to use an approach that Scott has successfully developed for livestock pests. In a recent study, Scott and his team tested it on the spotted-wing drosophila, an invasive fly that attacks soft-skinned fruit. The gene drive they developed for that study carried an edited version of the so-called doublesex gene, which is essential for the fly’s reproduction. In caged trials, they combined the engineered fly population with a population that didn’t have the gene edits, mimicking a real-world release. They found that the gene drive was copied at a rate of 94% to 99%—beyond the efficiency they had expected. ​“It was the first really efficient-homing gene drive for suppression of an agricultural pest,” says Scott. He hopes that a similar technique will work with screwworms and allow researchers to perform safer tests.

It won’t be a quick process. Assembling the gene-drive system, testing it, and securing approvals for field release could take many years, says Jackson Champer, a researcher at Peking University in Beijing, who is not part of the Uruguayan team. “It’s not an easy task; there have been many failed attempts at gene drives.” 

Menchaca agrees. He says he and his colleagues aim to integrate their system into the flies and validate the technology in two to three years, adding that they hope to seek permission for field testing and will consider inviting companies to participate in scaling up the technology in the future.

However, Esvelt hopes the Uruguayan researchers will one day be able to release and test their altered screwworms in the wild. He believes that Uruguay’s robust regulatory environment makes the country a likely site for such experiments.

“This would be a project run effectively by Uruguayans, for the benefit of Uruguay, and may be offered eventually—if it works well—to a broader array of folks throughout South America,” he says.

The next generation of mRNA vaccines is on its way

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

Welcome back to The Checkup! Today I want to talk about … mRNA vaccines.

I can hear the collective groan from here, but wait—hear me out! I know you’ve heard a lot about mRNA vaccines, but Japan recently approved a new one for covid. And this one is pretty exciting. Just like the mRNA vaccines you know and love, it delivers the instructions for making the virus’s spike protein. But here’s what makes it novel: it also tells the body how to make more mRNA. Essentially, it provides instructions for making more instructions. It’s self-amplifying.

I’ll wait while your head explodes.

Self-amplifying RNA vaccines (saRNA) offer a couple of important advantages over conventional mRNA vaccines, at least in theory. Because saRNA vaccines come with a built-in photocopier, the dose can be much lower. One team of researchers tested both an mRNA vaccine and an saRNA vaccine in mice and found that they could achieve equivalent levels of protection against influenza with just 1/64th the dose. Second, it’s possible that saRNA vaccines will induce a more durable immune response because the RNA keeps copying itself and  sticks around longer. While mRNA might last a day or two, self-amplifying RNA can persist for a month.

Lest you think that this is just a tweaked version of conventional mRNA, It’s not. “saRNA is a totally different beast,” Anna Blakney, a bioengineer at the University of British Columbia, told Nature. (Blakney was one of our 35 Innovators Under 35 in 2023.)

What makes it a different beast? Conventional mRNA vaccines consist of messenger RNA that carries the genetic code for covid’s spike protein. Once that mRNA enters the body, it gets translated into proteins by the same cellular machinery that translates our own messenger RNA. 

Self-amplifying mRNA vaccines contain a gene that encodes the spike protein as well as viral genes that code for replicase, the enzyme that serves as a photocopier. So one self-amplifying mRNA molecule can produce many more. The idea of a vaccine that copies itself in the body might sound a little, well, unnerving. But there are a few things I should make clear. Although the genes that give these vaccines the ability to self-amplify come from viruses, they don’t encode the information needed to make the virus itself. So saRNA vaccines can’t produce new viruses. And just like mRNA, saRNA degrades quickly in the body. It lasts longer than mRNA, but it doesn’t amplify forever. 

Japan approved the new vaccine, called LUNAR-COV19, in late November on the basis of results from a 16,000-person trial in Vietnam. Last month researchers published results of a head-to-head comparison between LUNAR-COV19 and Comirnaty, the mRNA vaccine from Pfizer-BioNTech. In that 800-person study, vaccinated participants received either five  micrograms of LUNAR-COV19 or 30 micrograms of Comirnaty as a fourth dose booster. Reactions to both shots tended to be mild and resolve quickly. But the self-amplifying mRNA shot did elicit antibodies in a greater percentage of people than Comirnaty. And a month out, antibody levels against Omicron BA.4/5 were higher in people who received LUNAR-COV19. That could be a signal of increased durability.

The company has already filed for approval in Europe. It’s also working on a self-amplifying mRNA vaccine for flu, both seasonal and pandemic. Other companies are exploring the possibility that self-amplifying mRNA might be useful in rare genetic conditions to replace missing proteins. Arcturus, the company that co-developed LUNAR-COV19 with the global biotech CSL, is also developing self-amplifying messenger RNA to treat ornithine transcarbamylase deficiency, a rare and life-threatening genetic disease. It’s an mRNA bonanza that will hopefully lead to better vaccines and new therapies. 

Another thing

Babies and AI learn language in very different ways. The former rely on a relatively small set of experiences. The latter relies on data sets that encompass a trillion words. But this week I wrote about a new study that shows AI can learn language like a baby—at least some aspects of language. The researchers found that a neural network trained on things a single child saw and heard over the course of a year and a half could learn to match words to the objects they represent. Here’s the story. 

Read more from MIT Technology Review’s archive

mRNA vaccines helped tackle covid, but they can help with so much more—malaria, HIV, TB, Zika, even cancer. Jessica Hamzelou wrote about their potential in January, and I followed up with a story after two mRNA researchers won a Nobel Prize. 

Using self-amplifying RNA isn’t the only way to make mRNA vaccines more powerful. Researchers are tweaking them in other ways that might help boost the immune response, writes Anne Trafton

From around the web

Elon Musk says his company Neuralink has implanted a brain chip in a person for the first time. The device is designed to allow people to control external devices like smartphones and computers with their thoughts. (Washington Post)

In August I  wrote about Vertex’s quest to develop a non-opioid pain pill. This week the company announced positive results from phase 3 trials. The company expects to seek regulatory approval in the coming months, and if approved, the drug is likely to become a blockbuster. (Stat)

In some rare cases, it appears that Alzheimer’s can be transmitted from one person to another. That’s the conclusion of a new study: it found that eight people who received growth hormone from the brains of cadavers before the 1980s had sticky beta-amyloid plaques in their brains, a hallmark of the disease. The growth hormone they received also contained these proteins. And when researchers injected these proteins into mice, the mice also developed amyloid plaques. (Science)